“We have focused on creating key growth drivers and have structured the company along those growth drivers,” says Kiran Mazumdar Shaw. (BCCL)…………. owner BIOCON
MY, DR AMC COMMENTS- BIOCON GREAT PERFORMANCE, U ARE EVERYWHERE
Kiran Mazumdar Shaw: We have focused on creating key growth drivers and have structured the company along those growth drivers. These growth drivers are beginning to deliver very strongly for us.
The first is our small molecule business vertical, which is about our historic statins and immunosuppressant’s API business. This particular vertical going forward is envisioned to go up the value chain along an ANDA path and we believe that will improve the quality of earnings in this particular vertical, which for a long time was under pressure because of commoditisation of statins.http://economictimes.indiatimes.com/opinion/interviews/small-molecule-api-biz-to-be-growth-drivers-for-company-kiran-mazumdar-shaw-biocon/articleshow/21975113.cms
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....

Reblogged this on MedCheminAustralia.
LikeLike
Reblogged this on MedCheminSingapore by Sushma Wang.
LikeLike
Reblogged this on MariaGairos–DRUGS.
LikeLike
Reblogged this on MedChemHot.Pakistan.
LikeLike
Reblogged this on MED.CHEM in BURMA.
LikeLike
Reblogged this on Vijaya Shastry Ph.D Physical Chemistry.
LikeLike
Reblogged this on Medicinal.Chem.AbrahamThomas.
LikeLike